For Healthcare Professionals

A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

clipboard-pencil

About the study

This is a single-center, randomized, double-blind, sequential-group, placebo-controlled study with six sequential single dose cohorts with ascending dose levels in healthy adult participants. This study will assess the safety, tolerability, the pharmacokinetics from single subcutaneous administrations of NNC0582-0001 and explores the pharmacodynamics in healthy participants. Participants will be randomized in a 3:1 ratio to receive a fixed single dose (1-day) of NNC0582 0001 or placebo by injections under the skin. Participants will be followed up for 52 weeks post dose.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Female of non-childbearing potential or male aged 18-55 years (both inclusive) at the time of signing informed consent.
  2. Body Mass Index (BMI) from 20.0 to 30.0 kilogram per square meter (kg/m^2) (both inclusive) at screening.
  3. Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  2. Glycated haemoglobin (HbA1c) greater than or equal to 5.7 percent (39 millimoles per mole [mmol/mol]) at screening.
  3. * Any of the below laboratory safety parameters at screening outside normal range, see laboratory provided reference ranges for specific values (re-screening or re-sampling is NOT allowed if the participant has failed one of the exclusion criteria related to laboratory parameters):

  4. Alanine aminotransferase (ALT)
  5. Aspartate aminotransferase (AST)
  6. Bilirubin
  7. Estimated glomerular filtration rate (eGFR) below 90 milliliters per minute per 1.73m^2 (mL/min/1.73m^2)
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall (+1) 866-867-7178Email iconEmail Study Center

Study Details


Contition

Healthy Volunteers

Age

18 - 55

Phase

PHASE1

Participants Needed

56

Est. Completion Date

Jun 2, 2025

Treatment Type

INTERVENTIONAL


Sponsor

Novo Nordisk A/S

ClinicalTrials.gov NCT Identifier

NCT05624580

Study Number

NN6582-4838

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.